Evaluation of the safety and efficacy of retinal organoid transplantation: a comprehensive consideration of morphological, functional, and transplant techniques

Shanshan Ye, Weiran Zhang, Quan Sun, Baoyue Mi, Hui Li, Liqun Chen, Hua XiaVisual 2025 · DOI

Abstract

Retinal degenerative diseases refer to a group of disorders characterized by the gradual degradation of retinal tissue structure and function. With their incidence on the rise, there is an urgent need to develop new therapeutic strategies. Retinal organoids, as an emerging technology with promising potential for the treatment of retinal degenerative diseases, play a crucial role in constructing a disease model and drug screening. Here, we review recent developments in retinal organoid research, focusing particularly on their application in transplantation methodologies. We aimed to optimize the implantation process of retinal organoids while qualitatively and quantitatively assessing the degree of visual function recovery. This evaluation intended to determine their potential and effectiveness in treating retinal diseases, thereby advancing the clinical application of organoid transplantation technologies. Although animal experiments have demonstrated that retinal organoids hold significant potential in improving retinal structure and function, there remains a lack of sufficient clinical evidence to support their application efficacy in humans. Therefore, future studies should further optimize implantation protocols for retinal organoids and refine the associated evaluation strategies, with the goal of integrating more clinical data. This will, in turn, provide a more robust evidence base for the application of retinal organoids in human subjects.

Introduction

This review paper, published in Visual Neuroscience (2025), provides a comprehensive roadmap for the next frontier in ophthalmology: using 3D retinal organoids to reverse blindness. By synthesizing recent breakthroughs in stem cell biology and surgical techniques, the authors outline how we can move from simply slowing retinal decay to actively rebuilding the visual system.

Applications of Retinal Organoids

Retinal organoids (ROs) represent a transformative technology in ophthalmology, offering a versatile platform for research and therapy. Beyond transplantation, they serve as critical tools for understanding human development, modeling diseases, and testing new interventions.

Overview of the diverse applications of retinal organoids, including developmental studies, disease modeling, drug screening, and transplantation.

The Challenge of Retinal Degeneration

Retinal degenerative diseases (RDDs), such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), are leading causes of incurable blindness worldwide. Because photoreceptors (PRs) in the human retina lack regenerative abilities, once they die, the visual link to the brain is severed.

While traditional cell therapies have attempted to "seed" the retina with new cells, 2D cell suspensions often fail to integrate because they lack the complex, layered architecture of a functional retina. Retinal organoids—3D structures grown from stem cells that mimic the eye’s natural development—offer a solution. However, the field faces a massive hurdle: how do we safely transplant these complex tissues and, more importantly, how do we prove they are actually "seeing"?

Methodological Approaches

The paper reviews and categorizes the current state-of-the-art in three main areas:

1. Organoid Induction

Techniques like SFEBq (serum-free floating culture of embryoid body-like aggregates) allow researchers to grow ROs from human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs). These 3D models develop stratified layers and outer segments that 2D cultures cannot achieve, closely mimicking the natural process of retinal development.

The stages of retinal development mimicked by organoid induction, from optic vesicle to lens formation.

2. Transplantation Strategies

The authors compare layered grafting (transplanting intact "sheets" of tissue to preserve polarity) versus cell suspension (dissociating the organoid into individual cells for easier injection).

3. Multimodal Evaluation

A core focus of the paper is the "Evaluation System." This includes:

  • Morphological: Using Optical Coherence Tomography (OCT) and Immunohistochemistry (IHC) to track graft survival and synapse formation.
  • Functional: Using Electroretinograms (ERG) to measure electrical activity and behavioral tests (like the Optokinetic Tracking test) to see if the animal reacts to visual stimuli.

Key Insights and Ideas

  • Architecture is Essential: The 3D structure of an organoid isn't just for show; the spatial orientation of photoreceptors is required for them to form functional synapses with the host’s remaining bipolar cells.
  • The "Material Exchange" Phenomenon: Researchers discovered that donor cells sometimes "rescue" host cells by transferring RNA or proteins rather than fully replacing them. Distinguishing between true integration and this biochemical support is vital for evaluating long-term efficacy.
  • The Developmental Window: There is a "Goldilocks" zone for transplantation. For human ROs, the optimal window appears to be around days 50–60 of differentiation.
  • Immune Privilege is a Myth: While the eye is "immunologically privileged," the act of surgery disrupts the blood-retinal barrier. The paper emphasizes that even autologous (patient-derived) transplants may require temporary immunosuppression to prevent graft failure.

Key Results

  • Animal Success: In various mouse and rat models, RO transplantation has successfully restored light-induced electrical responses (ERG) and improved visual behavior (e.g., the ability to navigate water tasks) within 2–3 weeks post-surgery.
  • Human Safety: The first human trials confirmed that hiPSC-derived retinal sheets are safe and do not trigger tumors or severe rejection over a two-year period.
  • The Efficacy Gap: Despite structural survival, significant functional vision recovery in humans has not yet been achieved, highlighting a disconnect between "biological integration" and "functional seeing."

Limitations and Future Work

The authors identify several "bottlenecks" that the field must solve:

  • Surgical Precision: RO sheets are diminutive and fragile. Developing custom micro-delivery tools is necessary to prevent mechanical damage during implantation.
  • Standardization: There is currently no "gold standard" for what constitutes a "good" organoid. The authors call for a standardized system for pre-surgical planning and post-surgical grading.
  • Cost and Scalability: Producing patient-specific hiPSCs is prohibitively expensive. Future work should focus on "off-the-shelf" HLA-matched organoid banks to make the therapy accessible.
  • The "Final Connection": While we can get cells to survive, ensuring they form a high-fidelity connection to the brain's visual cortex remains the ultimate challenge.

Summary updated

Abstract

Retinal degenerative diseases refer to a group of disorders characterized by the gradual degradation of retinal tissue structure and function. With their incidence on the rise, there is an urgent need to develop new therapeutic strategies. Retinal organoids, as an emerging technology with promising potential for the treatment of retinal degenerative diseases, play a crucial role in constructing a disease model and drug screening. Here, we review recent developments in retinal organoid research, focusing particularly on their application in transplantation methodologies. We aimed to optimize the implantation process of retinal organoids while qualitatively and quantitatively assessing the degree of visual function recovery. This evaluation intended to determine their potential and effectiveness in treating retinal diseases, thereby advancing the clinical application of organoid transplantation technologies. Although animal experiments have demonstrated that retinal organoids hold significant potential in improving retinal structure and function, there remains a lack of sufficient clinical evidence to support their application efficacy in humans. Therefore, future studies should further optimize implantation protocols for retinal organoids and refine the associated evaluation strategies, with the goal of integrating more clinical data. This will, in turn, provide a more robust evidence base for the application of retinal organoids in human subjects.
BibTeX
@inproceedings{ye2025evaluation,
  author = {Shanshan Ye and Weiran Zhang and Quan Sun and Baoyue Mi and Hui Li and Liqun Chen and Hua Xia},
  title = {{Evaluation of the safety and efficacy of retinal organoid transplantation: a comprehensive consideration of morphological, functional, and transplant techniques}},
  booktitle = {Visual},
  year = {2025},
  doi = {10.48130/vns-0025-0013},
}
Figure